Evidence map›Paper›PMID 29288416›Full record

ArticleInternational urology and nephrology2018

Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer.

Ayşegül Doğan, Selami Demirci, Dilek Telci, Serli Canikyan, Merve Kongur, Bülent Dede, Fikrettin Şahin

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ayşegül DoğanGenetics and Bioengineering Department, Faculty of Engineering, Yeditepe University, Kayisdagi, Istanbul, Turkey. aguldgn@gmail.com.
Selami DemirciGenetics and Bioengineering Department, Faculty of Engineering, Yeditepe University, Kayisdagi, Istanbul, Turkey.
Dilek TelciGenetics and Bioengineering Department, Faculty of Engineering, Yeditepe University, Kayisdagi, Istanbul, Turkey.
Serli CanikyanOnkim Stem Cell Technologies, Istanbul, Turkey.
Merve KongurAcıbadem Labcell, Stem Cell Laboratory and Umbilical Cord Blood Bank, Istanbul, Turkey.
Bülent DedeDepartment of Chemistry, Faculty of Sciences and Arts, Süleyman Demirel University, Isparta, Turkey.
Fikrettin ŞahinGenetics and Bioengineering Department, Faculty of Engineering, Yeditepe University, Kayisdagi, Istanbul, Turkey.

Funding

ISTKA İSTKA/2012/BIL-164
6 · The paper itself

Abstract

purposeRenal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased.

methodsIn the current study, anticancer activity of a novel heterodinuclear Cu(II)-Mn(II) complex (Schiff base-SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells.

resultsThe results revealed that the SB-P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB-P85 combination suppressed tumor formation and growth compared to baseline.

conclusionOverall, SB-P85 showed promising anticancer activity against RCC in vitro and in vivo.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCarcinoma, Renal CellCell Line, TumorCell ProliferationDrug CombinationsKidney NeoplasmsMicePoloxamerSchiff BasesTreatment OutcomeAntineoplastic AgentsDrug CombinationsPoloxamerSchiff BasesChemotherapyP85PluronicRenal cell carcinomaSchiff base

Identifiers

PMID29288416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.